ArticleOncology letters2015
Clinical investigation into the initial diagnosis and treatment of 1,168 lung cancer patients.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study.Medical oncology (Northwood, London, England) · 2015Trial
- A Prospective Exploratory Study of Functional Immunity Assessed by Pretreatment Interferon Gamma Release Assay in Relation to Different Systemic Therapies in Patients With Advanced-Stage NSCLC.JTO clinical and research reports · 2025Article
- Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.Frontiers in public health · 2022Article
- Methods of computed tomography screening and management of lung cancer in Tianjin: design of a population-based cohort study.Cancer biology & medicine · 2019Article
- Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice.Chinese journal of cancer · 2017Article
- Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer.OncoTargets and therapy · 2017Article
- ATPase inhibitory factor 1 expression is an independent prognostic factor in non-small cell lung cancer.American journal of cancer research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to analyse clinical data obtained from lung cancer patients, including the initial clinical symptoms upon diagnosis, duration of patient delay in presenting to a doctor, lung cancer stage, treatment strategy and prognosis. A retrospective analysis was conducted of the clinical features of 1,168 lung cancer patients who were initially diagnosed and treated at the Tumor Hospital of Shandong Province (Jinan, China) in 2009. The Kaplan-Meier method and multivariate Cox regression analysis were performed to analyse the influence of gender, age, predominant symptoms, histopathological or cytological type and clinical staging on the overall patient survival. The follow-up rate of the present study was 92.4%, and the 1-, 2- and 3-year survival rates were 80.4, 44.9 and 15.8%, respectively. Multivariate analysis demonstrated that the patient age, extent of the tumour (T stage), extent of lymph node spread (N stage), overall clinical stage and treatment strategy were independent risk factors associated with patient survival. The present study identified that the initial symptoms of lung cancer varied, patient delay was long, the lung cancer cases were diagnosed in late clinical stages and the prognosis was poor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.